Here is your NEWS-Line for Radiology Professionals eNewsletter. For the latest news, jobs, education and blogs, bookmark our news page and job board or to take us everywhere with you, save this link to your phone. Also, enjoy the latest issue of NEWS-Line magazine, always free.
Society of Interventional Radiology Publishes IVC Filter Guidelines
The Society of Interventional Radiology published new clinical practice guidelines that provide evidence-based recommendations on the use of inferior vena cava filters to treat venous thromboembolism (VTE).
“These guidelines allow physicians treating patients at risk of a pulmonary embolism to make evidence-based decisions about the use of IVC filters,” said John A. Kaufman, MD, MS, FSIR, the guidelines’ primary author and chair of the department of interventional radiology at Oregon Health & Science University in Portland. “Throughout the process, the multidisciplinary team followed a gold-standard methodology to ensure we reached the best possible consensus on VTE patient care.”
The guidelines advise against the routine placement of inferior vena cava (IVC) filters in most VTE cases where patients are being successfully treated with anticoagulants. However, if anticoagulation therapi
Read Full Article
Recently Published Study Shows Effective Treatment for Early-Stage Breast Cancer
The TARGIT Collaborative Group (TCG) is pleased to announce publication of the long-term results of the Targeted Intraoperative Radiotherapy Trial (TARGIT-A Trial) comparing partial breast single fraction targeted intraoperative radiotherapy (TARGIT-IORT) to 3-6 week post-operative whole breast radiotherapy, demonstrating equivalent long-term outcomes between the two treatments. The results of the trial were published on August 19, 2020 in the British Medical Journal (www.bmj.com/content/370/bmj.m2836).
We now have long-term proof that TARGIT-IORT is not only an effective—but in many ways superior—treatment for early-stage breast cancer. Every hospital where breast cancer surgery is performed should offer this form of radiation treatment.
The TARGIT-A Trial was a 2,298-patient multicenter, international, randomized controlled trial evaluating the use of TARGIT-IORT using the Intrabeam
Read Full Article
Why COVID-19 Infection Curves Behave so Unexpectedly
With the first COVID-19 epidemic peak behind them, many countries explained the decrease of infection numbers through non-pharmaceutical interventions. Phrases like "social distancing" and "flatten the curve" have become part of common vocabulary. Yet some explanations fell short: How could one explain the linear rise of infection curves, which many countries display after the first peak, in contrast to the S-shaped curves, expected from epidemiological models?
In a new paper published in PNAS (Proceedings of the National Academy of Sciences of the United States of America), scientists at the Complexity Science Hub Vienna (CSH) and the Medical University of Vienna are the first ones to offer an explanation for the linear growth of the infection curve.
"At the beginning of the pandemic, COVID-19 infection curves showed the expected exponential growth," says Stefan Thurner, CSH president
Read Full Article
AdvaMed Commends CMS Proposed Rule to Improve Coverage For Innovative, “Breakthrough” Technologies
Following issuance by the Centers for Medicare and Medicaid Services (CMS) of a proposed rule on Medicare coverage of innovative technologies, the Advanced Medical Technology Association (AdvaMed) issued the following statements from President and CEO Scott Whitaker and other medtech industry leaders commending the agency’s action:
“In order to incentivize innovative medical breakthroughs, the federal government must ensure those breakthrough technologies are covered by Medicare,” said Scott Whitaker, AdvaMed president and CEO. “We are pleased that this proposed rule gets us closer to this goal as it would help ensure the patients who need these innovative technologies have access to them. We thank HHS Secretary Azar and CMS Administrator Verma for their leadership. The Administration’s continued focus on the value of medical technology and innovative breakthroughs will without questio